Novartis’s Luxturna (voretigene neparvovec) Receives Health Canada Approval as the First Gene Replacement Therapy for Inherited Retinal Disease Published: Oct 15, 2020 | Tags: approval, Canada, health, Inherited Retinal Disease, Luxturna, Novartis, receives, voretigene neparvovec Galapagos & Servier’s GLPG1972/S201086 Fails to Meet its Primary Endpoint in P-II ROCCELLA Study for Knee Osteoarthritis Published: Oct 15, […]Read More
Shots: Lilly to acquire Disarm for $135M upfront and ~$1.225B as potential development regulatory and commercial milestones, making a total deal value of ~1.36B The acquisition will expand Lilly’s R&D efforts in pain and neurodegeneration with the addition of Disarm’s preclinical SARM1 programs for axonal degeneration Disarm is advancing its potent SARM1 inhibitors in preclinical […]Read More
1. Eisai And Biogen to Terminate Two P-III Clinical Studies of Elenbecestat (E2609) for Early Alzheimer’s Disease Published: Sept 13, 2019 | Tags: Eisai, Biogen, Terminate Two, P-III, Clinical Studies, Elenbecestat, E2609, Early Alzheimer’s Disease 2. GE Healthcare’s Critical Care Suite AI-Powered X-ray Device Receives FDA’s 510(k) Clearance to Identify Pneumothorax Published: Sept 12, 2019 | Tags: […]Read More
Shots: Lily and BI reports results of EMPA-REG OUTCOME trial assessing Jardiance (10/25 mg qd) vs PBO, from 42 countries in 7,020 patients with T2D at high risk for cardiovascular events EMPA-REG OUTCOME results: mean survival @age 45 yrs. (32.1 yrs vs 27.6yrs); @age 50,60,70 & 80yrs. (3.1,2.5, 2,1 yrs.) Jardiance is a prescription drug […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
